Compare Abbott Laboratories (ABT) vs Wells Fargo & Co (WFC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Wells Fargo & Co — how do they compare? Abbott Laboratories trades at $95.24 (market cap $166.94B), while Wells Fargo & Co trades at $85.71 (market cap $266.79B). The key difference: Wells Fargo & Co is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | WFC | |
|---|---|---|
Market Cap | $166.94B | $266.79B |
Sector | Health | Financials |
52-Week High | $136.62 | $96.40 |
52-Week Low | $82.57 | $73.42 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Wells Fargo (WFC) trades at $87.21, up 1.99% on the day, with a bullish technical signal from moving averages and oscillators. The stock shows solid fundamentals with a P/E of 13.52, net income margin of 25.53%, and ROE of 12.7%. Recent earnings have been mixed, with a beat in Q3 2025 but misses in Q4 2025 and Q1 2026. The company announced a dividend of $0.45 payable in June 2026, and Q2 2026 earnings are expected on July 14, 2026, with an EPS estimate of 1.73.
The outlook for WFC is cautiously optimistic, supported by analyst consensus with a $98.25 price target and 45% buy ratings. Key opportunities include potential earnings growth and dividend increases post-Fed stress tests. Risks involve volatile cash flows, regulatory changes impacting debit card fees, and competitive pressures in the banking sector. The stock's valuation remains attractive, but investors should monitor upcoming earnings for confirmation of growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
